Intriguingly, according to recent studies, in addition to traditional IL-1β inhibitors, NLRP3 or P2X7R blockers also reduce the release of cartilage destruction factor IL-1β, and alleviate joint inflammation by controlling macrophage or FLS pyroptosis (151–153), which increases the potential therapeutic targets of RA. This evidence concerns the gene NLRP3 and rheumatoid arthritis.